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Christopher J. Abularrage, Robert S. Crawford, Mark F. Conrad, Christo-
pher J. Kwolek, Richard P. Cambria, and Glenn M. LaMuraglia, From
Massachusetts General Hospital, Boston, Mass
Objectives: Persistent type 2 endoleaks (PT2) present6months after
endovascular aneurysm repair (EVAR) are associated with adverse out-
comes. This study evaluated the preoperative risk factors and natural history
of PT2 to define a population at high-risk.
Methods: From 1999 to 2007, 595 of 832 (72%) EVAR patients had
long-term computed tomography (CT) follow-up and comprised the study
cohort. Preoperative anatomic and clinical variables were correlated with PT2
using Cox regression and high-risk composite variable analyses. Primary end
points included spontaneous resolution, sac enlargement5mm, and freedom
from reintervention and were evaluated using Kaplan-Meier analysis.
Results: There were 136 (23%) PT2 patients with a median follow-up
of 34.8 months (range, 6.4-121.2 years). Predictive factors included patent
inferior mesenteric artery (IMA; odds ratio [OR], 4.18; 95% confidence
interval [CI], 1.69-10.31; P .002), increasing no of patent lumbar arteries
(OR, 1.25; 95% CI, 1.10-1.42; P  .0006), increasing age (OR, 1.04; 95%
CI, 1.01-1.06; P .003), and increasing aneurysm luminal diameter shown
on CT contrast opacified lumen (OR, 1.03; 95% CI, 1.02-1.05; P .0001).
High-risk composites indicated that patients with a patent IMA and either
Table. Patient comorbidities
Comorbidity % (N  323)
Hypertension 73.7
Coronary artery disease 44.3
Angina 4.3
Arrhythmia 26.9
Myocardial infarction 24.1
Congestive heart failure 7.4
COPD 21.7
Hyperlipidemia 44.9
Renal insufficiency 22.0
Peripheral vascular disease 9.6
Diabetes mellitus 11.1
Stroke 9.6
Smoking 63.2
Cancer 15.5
ASA class II 1.6
ASA class III 78.9
ASA class IV 19.5
ASA, American Society of Anesthesiologists; COPD, chronic obstructive
pulmonary disease
Fig. Freedom from abdominal aortic aneurysm-related death.6 patent lumbar arteries, maximum luminal diameter 30 mm, or age
70 years had an approximately 10-fold increased risk of PT2 (Table).Patients with a patent IMA and any two risk factors had an approximately
20-fold risk. During follow-up, spontaneous PT2 resolution occurred in 35
patients (26%), sac diameter remained stable in 63 (46%), and rupture
occurred in 2 (1.5%). By Kaplan-Meier analysis, 35% of PT2 resolve spon-
taneously and freedom from sac enlargement 5 mm is 55% at 5 years.
Fifty-nine reinterventions were performed in 39 patients with PT2. Freedom
from reintervention was 67% at 5 years.
Conclusions: Readily identifiable preoperative variables are associated
with PT2. High-risk composites can be used to identify a cohort of patients
that should be considered for perioperative interventions to preclude PT2.
Does Renal Transplantation Improve Endovascular Interventional
Outcomes for Patients with Chronic Renal Insufficiency?
Combiz Rezayat,a Ashley Graham,a Habib Khan,a James McKinsey,a
Nicholas Morrisey,a Rajeev Dayal,a Harry Bush,b John Karwowski,b and
Roman Nowygrod,a From Columbia University Medical Centera; and
Weill Cornell Medical College,b New York, NY
Introduction: It has been suggested that preemptive renal transplan-
tation can reduce the incidence and severity of peripheral vascular disease
(PVD) and improve limb salvage. Immunosuppressed transplant patients
may have a decreased incidence of in-stent restenosis. This study compared
limb salvage and patency rates after endovascular interventions among
patients with chronic renal insufficiency (CRI), functional and failed renal
transplants (RT), and normal renal (NR) function.
Methods: A database of 1567 treated lesions from 2004 to 2009 was
cross-referenced with the RT registry for the same period (n 2283) to select
three treated patient groups: NR, 1172; CRI (creatinine 1.2 mg/dL), 349
(end-stage renal disease, 92); RT, 46 (25 functional, 21 failed). Comorbidities
and indications, and primary, secondary patencies, and limb salvage at 6, 12, 18,
24 months were assessed. P was calculated by log-rank analysis.
Results: Indications for interventions were similar for CRI and RT,
comprising claudication, 28 (39%); rest pain, 14 (4%); and tissue loss, 58
(57%). TheNR group hadmore claudicant patients (52%) and less tissue loss
(34%; P  .0001). RT patients were younger than CRI patients and had
lower rates of heart failure. NR patients had a significantly lower incidence of
diabetes than CRI and RT patients (P .002). Primary patency for NR (78%
at 6 months; 50% at 24 months) was significantly better than for CRI (P 
.019 at 6 months; P .002 at 24 months). Primary and secondary patencies
at 6 and 24 months were significantly worse for the RT group than for the
NR group (P .001). Similarly, limb salvage at 24months for RT (67%) was
significantly worse than for NR (87%, P .0001) but did not reach statistical
significance for CRI (73%, P  .058). There was a nonsignificant trend
towards improved patency results in patients with functional vs failed RT.
Conclusions: As anticipated, endovascular outcomes for patency and
limb salvage in patients with CRI were significantly worse than in patients
with NR. Restoration of renal function by transplantation does not appear to
reverse these outcomes despite the postulated beneficial effect of systemic
immunosuppression.
Repeat Angioplasty and Stenting for Femoropopliteal Occlusive
Disease: Factors Affecting Outcomes of the Second-Time Endovascular
Intervention
William P. Robinson III, Louis L. Nguyen, Richard Bafford, and Michael
Belkin, From Brigham and Women’s Hospital, Boston, Mass
Introduction: Repeat percutaneous interventions for femoropopliteal
occlusive disease are common, but the outcomes are poorly understood. We
sought to determine the results of second-time femoropopliteal percutane-
Table. High-risk composite variable analysis
Composite variable OR (95% CI)
Patent inferior mesenteric artery and
MALD 30 mm 9.15 (3.37-24.98)
6 patent LA 9.43 (3.59-24.86)
Age 70 y 9.71 (3.44-27.40)
MALD 30 mm  6 patent LA 18.49 (6.41-53.59)
MALD 30 mm  age 70 years 19.04 (6.19-8.74)
6 patent LA  age 70 years 19.62 (6.55-58.67)
MALD 30 mm  6 patent LA
 age 70 y
38.46 (11.84-125.23)
CI, Confidence interval; LA, lumbar arteries; MALD, maximum aneurysm
luminal diameter; OR, odds ratio.ous transluminal angioplasty/stenting (SPTAS) and identify factors associ-
ated with outcome.
